The Journal of Pain
Volume 10, Issue 2 , Pages 147-159.e15 , February 2009

Research Gaps on Use of Opioids for Chronic Noncancer Pain: Findings From a Review of the Evidence for an American Pain Society and American Academy of Pain Medicine Clinical Practice Guideline

  • Roger Chou

      Affiliations

    • The Oregon Evidence-Based Practice Center, Department of Medicine, Department of Medical Informatics and Clinical Epidemiology, Oregon Health and Science University, Portland, Oregon
    • Corresponding Author InformationAddress reprint requests to Dr Roger Chou, 3181 SW Sam Jackson Park Road, Mail code BICC, Portland, OR 97239.
    • ,
  • Jane C. Ballantyne

      Affiliations

    • Division of Pain Medicine, Department of Anesthesia and Critical Care, Massachusetts General Hospital, Boston, Massachusetts
    • ,
  • Gilbert J. Fanciullo

      Affiliations

    • Pain Management Center, Department of Anesthesiology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
    • ,
  • Perry G. Fine

      Affiliations

    • Pain Research Center, Department of Anesthesiology, University of Utah, Salt Lake City, Utah
    • ,
  • Christine Miaskowski

      Affiliations

    • Department of Physiological Nursing, School of Nursing, University of California, San Francisco, California

References 

  1. Ackerman SJ, Knight T, Schein J, Carter C, Staats P. Risk of constipation in patients prescribed fentanyl transdermal system or oxycodone hydrochloride controlled-release in a California Medicaid population. Consult Pharm. 2004;19:118–132
  2. Adams LL, Gatchel RJ, Robinson RC, Polatin P, Gajraj N, Deschner M, et al. Development of a self-report screening instrument for assessing potential opioid medication misuse in chronic pain patients. J Pain Symptom Manage. 2004;27:440–459
  3. Akbik H, Butler SF, Budman SH, Fernandez K, Katz NP, Jamison RN. Validation and clinical application of the Screener and Opioid Assessment for Patients with Pain (SOAPP). J Pain Symptom Manage. 2006;32:287–293
  4. Allan L, Richarz U, Simpson K, Slappendel R. Transdermal fentanyl versus sustained release oral morphine in strong-opioid naive patients with chronic low back pain. Spine. 2005;30:2484–2490
  5. Angst MS, Clark JD. Opioid-induced hyperalgesia: A qualitative systematic review. Anesthesiology. 2006;104:570–587
  6. Atluri SL, Sudarshan G. Development of a screening tool to detect the risk of inappropriate prescription opioid use in patients with chronic pain. Pain Physician. 2004;7:333–338
  7. Attal N, Guirimand F, Brasseur L, Gaude V, Chauvin M, Bouhassira D. Effects of IV morphine in central pain: A randomized placebo-controlled study. Neurology. 2002;58:554–563
  8. Babul N, Provencher L, Laberge F, Harsanyi Z, Moulin D. Comparative efficacy and safety of controlled-release morphine suppositories and tablets in cancer pain. J Clin Pharmacol. 1998;38:74–81
  9. Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med. 2003;349:1943–1953
  10. Beaver WT, Wallenstein SL, Houde RW, Rogers A. A clinical comparison of the analgesic effects of methadone and morphine administered intramuscularly, and of orally and parenterally administered methadone. Clin Pharmacol Ther. 1967;8:415–426
  11. Beaver WT, Wallenstein SL, Houde RW, Rogers A. A clinical comparison of the effects of oral and intramuscular administration of analgesics: pentazocine and phenazocine. Clin Pharmacol Ther. 1968;9:582–597
  12. Becker G, Galandi D, Blum HE. Peripherally acting opioid antagonists in the treatment of opiate-related constipation: A systematic review. J Pain Symptom Manage. 2007;34:547–565
  13. Belgrade MJ, Schamber CD, Lindgren BR. The DIRE score: Predicting outcomes of opioid prescribing for chronic pain. J Pain. 2006;7:671–681
  14. Bombardier C, Esmail R, Nachemson AL. the Back Review Group Editorial Board: The Cochrane Collaboration Back Review Group of Spinal Disorders. Spine. 1997;22:837–840
  15. Bouter LM, Pennick V, Bombardier C. the Editorial Board of the Back Review Group: Cochrane Back Review Group. Spine. 2003;28:1215–1218
  16. British Pain Society . Recommendations for the Appropriate Use of Opioids for Persistent Non-cancer Pain (the first revised edition). London: The British Pain Society; March 2005;
  17. Butler SF, Budman SH, Fernandez K, Jamison RN. Validation of a screener and opioid assessment measure for patients with chronic pain. Pain. 2004;112:65–75
  18. Butler SF, Budman SH, Fernandez KC, Houle B, Benoit C, Katz N, et al. Development and validation of the Current Opioid Misuse Measure. Pain. 2007;130:144–156
  19. Butler SF, Fernandez K, Benoit C, Budman SH, Jamison RN. Validation of the revised screener and opioid assessment for patients with pain (SOAPP-R). J Pain. 2008;9:360–372
  20. Byas-Smith MG, Chapman SL, Reed B, Cotsonis G. The effect of opioids on driving and psychomotor performance in patients with chronic pain. Clin J Pain. 2005;21:345–352
  21. Caudill-Slosberg MA, Schwartz LM, Woloshin S. Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs 2000. Pain. 2004;109:514–519
  22. Center for Substance Abuse Treatment. Methadone-associated mortality: Report of a national assessment. May 2003
  23. Office of Applied Studies, Substance Abuse and Mental Health Service Administration . Results from the 2004 National Survey on Drug Use and Health. Rockville, MD: Department of Health and Human Services; 2005;
  24. Centers for Disease Control and Prevention: Unintentional poisoning deaths–United States, 1999-2004. Morb Mortal Wkly Rep. 2007;56:93–96
  25. Cepeda MS, Camargo F, Zea C, Valencia L. Tramadol for osteoarthritis. Cochrane Database Syst Rev. 2006;CD005522
  26. Chou R, Clark E, Helfand M. Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: A systematic review. J Pain Symptom Manage. 2003;26:1026–1048
  27. Chou R, Fanciullo G, Fine PG, Miaskowski C, Passik S, Portenoy P. Opioids for chronic noncancer pain: Prediction and identification of aberrant drug-related behaviors: A review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009;10:131–146
  28. Chou R, Huffman L. The use of opioids for chronic non-cancer pain: Evidence review. American Pain Society. 2009;(in press)
  29. Chugh SS, Socoteanu C, Reinier K, Waltz J, Jui J, Gunson K. A community-based evaluation of sudden death associated with therapeutic levels of methadone. Am J Med. 2008;121:66–71
  30. Clark AJ, Ahmedzai SH, Allan LG, Camacho F, Horbay GL, Richarz U, et al. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Curr Med Res Opin. 2004;20:1419–1428
  31. Compton P, Darakjian J, Miotto K. Screening for addiction in patients with chronic pain and “problematic” substance use: Evaluation of a pilot assessment tool. J Pain Symptom Manage. 1998;16:355–363
  32. Corey DT. A limited functional restoration program for injured workers: A randomised trial. J Occup Rehabil. 1996;6:239–249
  33. Cowan DT, Wilson-Barnett J, Griffiths P, Vaughan DJ, Gondhia A, Allan LG. A randomized, double-blind, placebo-controlled, cross-over pilot study to assess the effects of long-term opioid drug consumption and subsequent abstinence in chronic noncancer pain patients receiving controlled-release morphine. Pain Med. 2005;6:113–121
  34. Cruciani RA, Sekine R, Homel P, Lussier D, Yap Y, Suzuki Y, et al. Measurement of QTc in patients receiving chronic methadone therapy. J Pain Symptom Manage. 2005;29:385–391
  35. Daniell HW. DHEAS deficiency during consumption of sustained-action prescribed opioids: Evidence for opioid-induced inhibition of adrenal androgen production. J Pain. 2006;7:901–907
  36. Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain. 2002;3:377–384
  37. Daniell HW. Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. J Pain. 2008;9:28–36
  38. De Conno F, Ripamonti C, Saita L, MacEachern T, Hanson J, Bruera E. Role of rectal route in treating cancer pain: A randomized crossover clinical trial of oral versus rectal morphine administration in opioid-naive cancer patients with pain. J Clin Oncol. 1995;13:1004–1008
  39. Dellemijn PL, van Duijn H, Vanneste JA. Prolonged treatment with transdermal fentanyl in neuropathic pain. J Pain Symptom Manage. 1998;16:220–229
  40. Deshpande A, Furlan AD, Mailis-Gagnon A, Atlas S, Turk D. Opioids for chronic low-back pain. Cochrane Database Syst Rev. 2007;CD004959
  41. Devulder J, Richarz U, Nataraja SH. Impact of long-term use of opioids on quality of life in patients with chronic, non-malignant pain. Curr Med Res Opin. 2005;21:1555–1568
  42. Dunbar SA, Katz NP. Chronic opioid therapy for nonmalignant pain in patients with a history of substance abuse: Report of 20 cases. J Pain Symptom Manage. 1996;11:163–171
  43. Edwards RR, Haythornthwaite JA, Tella P, Max MB, Raja S. Basal heat pain thresholds predict opioid analgesia in patients with postherpetic neuralgia. Anesthesiology. 2006;104:1243–1248
  44. Eisenberg E, McNicol EW, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: Systematic review and meta-analysis of randomized controlled trials. JAMA. 2005;293:3043–3052
  45. Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Are opioid-dependent/tolerant patients impaired in driving-related skills? A structured evidence-based review. J Pain Symptom Manage. 2003;25:559–577
  46. Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Can patients taking opioids drive safely? A structured evidence-based review. J Pain Palliat Care Pharmacother. 2002;16:9–28
  47. Fishman SM, Bandman TB, Edwards A, Borsook D. The opioid contract in the management of chronic pain. J Pain Symptom Manage. 1999;18:27–37
  48. Flor H, Fydrich T, Turk DC. Efficacy of multidisciplinary pain treatment centers: A meta-analytic review. Pain. 1992;49:221–230
  49. Franklin GM, Mai J, Wickizer T, Turner JA, Fulton-Kehoe D, Grant L. Opioid dosing trends and mortality in Washington State workers' compensation, 1996-2002. Am J Ind Med. 2005;48:91–99
  50. Fredheim OM, Kaasa S, Dale O, Klepstad P, Landro NI, Borchgrevink PC. Opioid switching from oral slow release morphine to oral methadone may improve pain control in chronic non-malignant pain: A nine-month follow-up study. Palliat Med. 2006;20:35–41
  51. Freye E, Anderson-Hillemacher A, Ritzdorf I, Levy JV. Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients. Pain Pract. 2007;7:123–129
  52. Furlan AD, Clarke J, Esmail R, Sinclair S, Irvin E, Bombardier C. A critical review of reviews on the treatment of chronic low back pain. Spine. 2001;26:E155–E162
  53. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: A meta-analysis of effectiveness and side effects. CMAJ. 2006;174:1589–1594
  54. Gaertner J, Radbruch L, Giesecke T, Gerbershagen H, Petzke F, Ostgathe C, et al. Assessing cognition and psychomotor function under long-term treatment with controlled release oxycodone in non-cancer pain patients. Acta Anaesthesiol Scand. 2006;50:664–672
  55. Galski T, Williams JB, Ehle HT. Effects of opioids on driving ability. J Pain Symptom Manage. 2000;19:200–208
  56. Gartlehner G, Hansen RA, Nissman D, Lohr KN, Carey TS. A simple and valid tool distinguished efficacy from effectiveness studies. J Clin Epidemiol. 2006;59:1040–1048
  57. Graziotti P, Goucke R. The use of oral opioids in patients with chronic nonmalignant pain: Management strategies. Med J Austr. 1997;167:30–34
  58. GSK, Adolor, London and Exton PU: GSK and Adolor announce preliminary results from phase 3 safety study of Alvimopan (Entereg/Entrareg). Available at: http://www.gsk.com/media/pressreleases/2007/2007_04_09_GSK1012.htm. Accessed April 9, 2007
  59. Guzman J, Esmail R, Karjalainen K, Malmivaara A, Irvin E, Bombardier C. Multidisciplinary rehabilitation for chronic low back pain: Systematic review. BMJ. 2001;322:1511–1516
  60. Hale M, Speight K, Harsanyi Z, Iwan T, Slagle N, Lacouture P, et al. Efficacy of 12 hourly controlled-release codeine compared with as required dosing of acetaminophen plus codeine in patients with chronic low back pain. Pain Res Manag. 1997;2:33–38
  61. Hale ME, Dvergsten C, Gimbel J. Efficacy and safety of oxymorphone extended release in chronic low back pain: Results of a randomized, double-blind, placebo- and active-controlled phase III study. J Pain. 2005;6:21–28
  62. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, et al. Current methods of the third US Preventive Services Task Force. Am J Prev Med. 2001;20:21–35
  63. Hartung DM, Middleton L, Haxby DG, Koder M, Ketchum KL, Chou R. Rates of adverse events of long-acting opioids in a state Medicaid program. Ann Pharmacother. 2007;41:921–928
  64. Hays H. Use of methadone in treating chronic noncancer pain. Pain Res Manag. 1999;4:23–27
  65. Hoffman BM, Chatkoff DK, Papas RK, Kerns RD. Meta-analysis of psychological interventions for chronic low back pain. Health Psychol. 2007;26:1–9
  66. Hojsted J, Sjogren P. Addiction to opioids in chronic pain patients: A literature review. Eur J Pain. 2007;11:490–518
  67. Hollingshead J, Duhmke R, Cornblath D. Tramadol for neuropathic pain. Cochrane Database Syst Rev. 2006;CD003726
  68. Holmes CP, Gatchel RJ, Adams LL, Stowell AW, Hatten A, Noe C, et al. An opioid screening instrument: Long-term evaluation of the utility of the Pain Medication Questionnaire. Pain Pract. 2006;6:74–88
  69. Huse E, Larbig W, Flor H, Birbaumer N. The effect of opioids on phantom limb pain and cortical reorganization. Pain. 2001;90:47–55
  70. Jadad AR, McQuay HJ. Meta-analyses to evaluate analgesic interventions: A systematic qualitative review of their methodology. J Clin Epidemiol. 1996;49:235–243
  71. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Control Clin Trials. 1996;17:1–12
  72. Jamison RN, Raymond SA, Slawsby EA, Nedeljkovic SS, Katz NP. Opioid therapy for chronic noncancer back pain: A randomized prospective study. Spine. 1998;23:2591–2600
  73. Johnson M, Mortimer S, Bogle S, Hallam SJ. A study to compare subject acceptability of Duragesic with sustained release morphine in subjects requiring strong opioids for chronic non-malignant pain. Available at: http://www.janssen-cilag.com/content/backgrounders/janssen-cilag.com/SynopsisFEN-GBR-21.pdf. Accessed May 29, 2007
  74. Jovey RD, Ennis J, Gardner-Nix J, Goldman B, Hays H, Lynch M, et al. Use of opioid analgesics for the treatment of chronic noncancer pain: A consensus statement and guidelines from the Canadian Pain Society, 2002. Pain Res Manag. 2003;8:3A–28A
  75. Kalso E, Allan L, Dellemijn PL, Faura CC, Ilias WK, Jensen TS, et al. European Federation of Chapters of the International Association for the Study of Pain: Recommendations for using opioids in chronic non-cancer pain. Eur J Pain. 2003;7:381–386
  76. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: Systematic review of efficacy and safety. Pain. 2004;112:372–380
  77. Kalso E, Simpson KH, Slappendel R, Dejonckheere J, Richarz U. Predicting long-term response to strong opioids in patients with low back pain: Findings from a randomized, controlled trial of transdermal fentanyl and morphine. BMC Med. 2007;5:39
  78. Karjalainen K, Malmivaara A, van Tulder MW, Roine R, Jauhiainen M, Hurri H, et al. Multidisciplinary biopsychosocial rehabilitation for subacute low back pain in working-age adults: A systematic review within the framework of the Cochrane Collaboration Back RevIew Group. Spine. 2001;26:262–269
  79. Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med. 2002;137:501–504
  80. Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, van der Meulen JH, et al. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA. 1999;282:1061–1066
  81. Maier C, Hildebrandt J, Klinger R, Henrich-Eberl C, Lindena G. Morphine responsiveness, efficacy and tolerability in patients with chronic non-tumor associated pain: Results of a double-blind placebo-controlled trial (MONTAS). Pain. 2002;97:223–233
  82. Manchikanti L, Pampati V, Damron KS, McManus CD. Evaluation of variables in illicit drug use: does a controlled substance abuse screening tool identify illicit drug use?. Pain Physician. 2004;7:71–75
  83. Martell B. Systematic review: Opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med. 2007;146:116–127
  84. Matsumoto AK, Babul N, Ahdieh H. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: Results of a randomized, double-blind, placebo- and active-controlled phase III trial. Pain Med. 2005;6:357–366
  85. McCracken LM, Turk DC. Behavioral and cognitive-behavioral treatment for chronic pain: Outcome, predictors of outcome, and treatment process. Spine. 2002;27:2564–2573
  86. McGinn TG, Guyatt GH, Wyer PC, Naylor CD, Stiell IG, Richardson WS. Users' guides to the medical literature XXII: How to use articles about clinical decision rules. JAMA. 2000;284:79–84
  87. McNicol E, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: A systematic review. J Pain. 2003;4:231–256
  88. McNicol ED, Boyce D, Schumann R, Carr DB. Mu-opioid antagonists for opioid-induced bowel dysfunction. Cochrane Database Syst Rev. 2008;CD006332
  89. Menefee LA, Frank ED, Crerand C, Jalali S, Park J, Sanschagrin K, et al. The effects of transdermal fentanyl on driving, cognitive performance, and balance in patients with chronic nonmalignant pain conditions. Pain Med. 2004;5:42–49
  90. Mercadante S, Arcuri E, Fusco F, Tirelli W, Villari P, Bussolino C, et al. Randomized double-blind, double-dummy crossover clinical trial of oral tramadol versus rectal tramadol administration in opioid-naive cancer patients with pain. Support Care Cancer. 2005;13:702–707
  91. Mercadante S, Portenoy RK. Opioid poorly-responsive cancer pain, 1: Clinical considerations. J Pain Symptom Manage. 2001;21:144–150
  92. Michna E, Ross EL, Hynes WL, Nedeljkovic SS, Soumekh S, Janfaza D, et al. Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. J Pain Symptom Manage. 2004;28:250–258
  93. Moher D, Pham B, Klassen TP, Schulz KF, Berlin JA, Jadad AR, et al. What contributions do languages other than English make on the results of meta-analyses?. J Clin Epidemiol. 2000;53:964–972
  94. Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: Systematic review of randomised trials of oral opioids. Arthritis Res Ther. 2005;7:R1046–R1051
  95. Morley JS, Bridson J, Nash TP, Miles JB, White S, Makin MK. Low-dose methadone has an analgesic effect in neuropathic pain: A double-blind randomized controlled crossover trial. Palliat Med. 2003;17:576–587
  96. Morley S, Eccleston C, Williams A. Systematic review and meta-analysis of randomized controlled trials of cognitive behaviour therapy and behaviour therapy for chronic pain in adults, excluding headache. Pain. 1999;80:1–13
  97. Nicholson B, Ross E, Weil A, Sasaki J, Sacks G. Treatment of chronic moderate-to-severe non-malignant pain with polymer-coated extended-release morphine sulfate capsules. Curr Med Res Opin. 2006;22:539–550
  98. Niemann T, Madsen LG, Larsen S, Thorsgaard N. Opioid treatment of painful chronic pancreatitis: Transdermal fentanyl versus sustained-release morphine. Int J Pancreatol. 2000;27:235–240
  99. Noble M, Tregear SJ, Treadwell JR, Schoelles K. Long-term opioid therapy for chronic noncancer pain: A systematic review and meta-analysis of efficacy and safety. J Pain Symptom Manage. 2008;35:214–228
  100. Olsen Y, Daumit GL, Ford DE. Opioid prescriptions by US primary care physicians from 1992 to 2001. J Pain. 2006;7:225–235
  101. Oregon Department of Human Services . Methadone deaths (and distribution) on the rise. CD Summary. 2003;52(14):
  102. Ostelo RW, van Tulder MW, Vlaeyen JW, Linton SJ, Morley SJ, Assendelft WJ. Behavioural treatment for chronic low-back pain. Cochrane Database of Syst Rev. 2005;CD002014
  103. Oxman AD, Guyatt GH. Validation of an index of the quality of review articles. J Clin Epidemiol. 1991;44:1271–1278
  104. Paulson DM, Kennedy DT, Donovick RA, Carpenter RL, Cherubini M, Techner L, et al. Alvimopan: An oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction-a 21-day treatment-randomized clinical trial. J Pain. 2005;6:184–192
  105. Peters J, Large RG, Elkind G. Follow-up results from a randomised controlled trial evaluating in- and outpatient pain management programmes. Pain. 1992;50:41–50
  106. Petrone D, Kamin M, Olson W. Slowing the titration rate of tramadol HCl reduces the incidence of discontinuation due to nausea and/or vomiting: A double-blind randomized trial. J Clin Pharm Ther. 1999;24:115–123
  107. Portenoy R. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study. Curr Med Res Opin. 2007;23:223–233
  108. Portenoy R, Farrar J, Backonja M, Cleeland C, Yang K, Friedman M, et al. Long-term use of controlled-release oxycodone for noncancer pain: Results of a 3-year registry study. Clin J Pain. 2007;23:287–299
  109. Portenoy RK, Thomas J, Boatwright MLMB, Tran D, Galasso FL, Stambler N, et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: A double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage. 2008;35:458–468
  110. Quang-Cantagrel ND, Wallace MS, Magnuson SK. Opioid substitution to improve the effectiveness of chronic noncancer pain control: A chart review. Anesth Analg. 2000;90:933–937
  111. Raja SN, Haythornthwaite JA, Pappagallo M, Clark MR, Travison TG, Sabeen S, et al. Opioids versus antidepressants in postherpetic neuralgia: A randomized, placebo-controlled trial. Neurology. 2003;59:1015–1021
  112. Ralphs JA, Williams AC, Richardson PH, Pither CE, Nicholas MK. Opiate reduction in chronic pain patients: A comparison of patient-controlled reduction and staff controlled cocktail methods. Pain. 1994;56:279–288
  113. Rauck RL. The ACTION study: A randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin) for the treatment of chronic, moderate to severe low back pain. J Opioid Manag. 2006;2:155–166
  114. Rauck RL. A randomized, open-label, multicenter trial comparing once-a-day AVINZA (morphine sulfate extended-release capsules) versus twice-a-day OxyContin (oxycodone hydrochloride controlled-released tablets) for the treatment of chronic, moderate to severe low back pain: Improved physical functioning in the ACTION trial. J Opioid Manag. 2007;3:35–43
  115. Ruoff GE. Slowing the initial titration rate of tramadol improves tolerability. Pharmacotherapy. 1999;19:88–93
  116. Sabatowski R, Schwalen S, Rettig K, Herberg KW, Kasper SM, Radbruch L. Driving ability under long-term treatment with transdermal fentanyl. J Pain Symptom Manage. 2003;25:38–47
  117. Salzman RT, Brobyn RD. Long-term comparison of suprofen and propoxyphene in patients with osteoarthritis. Pharmacology. 1983;27(Suppl 1):55–64
  118. Salzman RT, Roberts MS, Wild J, Fabian C, Reder RF, Goldenheim PD. Can a controlled release oral dose form of oxycodone be used as readily as an immediate release form for the purpose of titrating to stable pain control?. J Pain Symptom Manage. 1999;18:271–279
  119. Sandoval JA, Furlan AD, Mailis-Gagnon A. Oral methadone for chronic noncancer pain: A systematic literature review of reasons for administration, prescription patterns, effectiveness, and side effects. Clin J Pain. 2005;21:503–512
  120. Saper JR, Lake AE, Hamel RL, Lutz TE, Branca B, Sims DB, et al. Daily scheduled opioids for intractable head pain: Long-term observations of a treatment program. Neurology. 2004;62:1687–1694
  121. Schonstein E, Kenny DT, Keating J, Koes BW. Work conditioning, work hardening and functional restoration for workers with back and neck pain. Cochrane Database Syst Rev. 2003;CD001822
  122. Sigler K. Effect of a triplicate prescription law on prescribing of Schedule II drugs. Am J Hosp Pharm. 1984;41:108–111
  123. Simpson DM, Messina J, Xie F, Hale M. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: A multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29:588–601
  124. Staats PS, Markowitz J, Schein J. Incidence of constipation associated with long-acting opioid therapy: A comparative study. South Med J. 2004;97:129–134
  125. Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA. 2003;290:2443–2454
  126. Takkouche B, Montes-Martinez A, Gill SS, Etminam M. Psychotropic medications and the risk of fracture: A meta-analysis. Drug Saf. 2007;30:171–184
  127. Tennant FS, Rawson RA, Miranda L, Obert J. Outpatient treatment of prescription opioid dependence: Comparison of two methods. NIDA Res Monogr. 1983;43:315–321
  128. Management of Opioid Therapy for Chronic Pain Working Group. VA/DoD Clinical Practical Guidelines for the management of opioid therapy for chronic pain. Contract Number. 2003;V101(93)P-1633(version 1.0)
  129. Thomas JA, Karver S, Cooney GA, Chamberlain BH, Watt CK, Slatkin NE, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358:2332–2343
  130. Thomsen AB, Becker N, Eriksen J. Opioid rotation in chronic non-malignant pain patients: A retrospective study. Acta Anaesth Scand. 1999;43:918–923
  131. Toma M, McAlister FA, Bialy L, Adams DB, Vandermeer B, Armstrong PW. Transition from meeting abstract to full-length journal article for randomized controlled trials. JAMA. 2006;295:1281–1287
  132. Trescot AM, Boswell MV, Atluri SL, Hansen HC, Deer TR, Abdi S, et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician. 2006;9:1–39
  133. United States General Accounting Office (GAO): Prescription drugs: State monitoring programs provide useful tool to reduce diversion. Report to the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives: May 17, 2002
  134. van Tulder M, Furlan AD, Bombardier C, Bouter L. The Editorial Board of the Cochrane Collaboration Back Review Group: Updated method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group. Spine. 2003;28:1290–1299
  135. van Tulder MW, Vlaeyen JW, Linton SJ, Morley SJ, Assendelft WJ. Behavioral treatment for chronic low back pain. Cochrane Database of Syst Rev. 2005;CD002014
  136. Verhaak PF, Kerssens JJ, Dekker J, Sorbi MJ, Bensing JM. Prevalence of chronic benign pain disorder among adults: A review of the literature. Pain. 1998;77:231–239
  137. Wasan AD, Butler SF, Budman SH, Benoit C, Fernandez K, Jamison RN. Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain. Clin J Pain. 2007;23:307–315
  138. Wastila L. The influence of multiple copy prescription programs on analgesic utilization. J Pharm Care Pain Symp Cont. 1996;4:3–19
  139. Webster LR, Butera PG, Moran LV, Wu N, Burns LH, Friedmann N. Oxytrex minimizes physical dependence while providing effective analgesia: A randomized controlled trial in low back pain. J Pain. 2006;7:937–946
  140. Webster L, Jansen JP, Peppin J, Lasko B, Irving G, Morlion B, et al. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-included bowel dysfunction: Results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain. 2008;137:428–440
  141. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: Preliminary validation of the Opioid Risk Tool. Pain Med. 2005;6:432–442
  142. Whiting P, Rutjes A, Reitsma J, Glas A, Bossuyt P, Kleijnen J. Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern Med. 2004;140:189–202
  143. Wiedemer NL, Harden PS, Arndt IO, Gallagher RM. The opioid renewal clinic: A primary care, managed approach to opioid therapy in chronic pain patients at risk for substance abuse. Pain Med. 2007;8:573–584
  144. Wu SM, Compton P, Bolus R, Schieffer B, Pham Q, Baria A, et al. The Addiction Behaviors Checklist: Validation of a new clinician-based measure of inappropriate opioid use in chronic pain. J Pain Symptom Manage. 2006;32:342–351

 Editor's Note: The American Pain Society and the American Academy of Pain Medicine present this final article in this 3-part report as a guideline for opioid treatment of noncancer pain.

 This article is based on research conducted at the Oregon Evidence-based Practice Center, with funding from the American Pain Society (APS). The authors are solely responsible for the content of this article and the decision to submit for publication. No statement in this article should be construed as an official position of the APS or the American Academy of Pain Medicine. The authors have no known or potential conflicts of interest to declare.

PII: S1526-5900(08)00830-4

doi: 10.1016/j.jpain.2008.10.007

The Journal of Pain
Volume 10, Issue 2 , Pages 147-159.e15 , February 2009

Article Tools